Inflammatory Cellular Trafficking in Asthma in Response to Segmental Allergen Challenge

Who is this study for? Patients with asthma in response to segmental allergen challenge
What treatments are being studied? Bronchoscopy+Segmental Allergen Challenge+Broncheoalveolar Lavage
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

Asthma is a heterogeneous disorder in which multiple potential inflammatory pathways contribute to airway obstruction. The biological basis for airway inflammation is the subject of intensive investigation. This work is designed to identify airway factors that are responsible for recruiting cells and associate their airway presence with atopy and asthma.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: t
View:

• All subjects will have a baseline FEV1 determined at the characterization visit that is no less than 75 % of the predicted value.

• All subjects will have a clinical history of allergic symptoms to cat or dust mite allergen and demonstrated skin reactivity (a positive allergen prick test).

• Life-long absence of cigarette smoking (defined as a lifetime total of less than 5 pack-years); none in 5 years).

• Willing and able to give informed consent.

• Expressed the desire to participate in an interview with the principal investigator.

• Age between 18 and 50 years.

• ANA subjects will have a history of either (a) allergic rhinitis (with one or more of the following symptoms: nasal congestion, sneezing, runny nose, postnasal drainage), (b) allergic conjunctivitis (ocular itching, tearing and/or swelling) or (c) contact allergy associated with cat dander or dust mite and a positive allergy test to the same allergen.

• All subjects will have a baseline FEV1 and FVC determined at the characterization visit that is no less than 90 % of the predicted value.

• All subjects will have a positive allergy skin prick test to cat dander or dust mite allergen.

• All subjects will be in good general health.

• Life-long absence of cigarette smoking (defined as a lifetime total of less than 5 pack-years and none in 5 years).

• Willing and able to give informed consent.

• Expressed the desire to participate in an interview with the principal investigator.

• Age between 18 and 50 years.

Locations
United States
Massachusetts
Massachusetts General Hospital
RECRUITING
Boston
Contact Information
Primary
Daniel L Hamilos, MD
dhamilos@partners.org
617-726-5090
Backup
Benjamin D Medoff, MD
bmedoff@partners.org
617-726-6695
Time Frame
Start Date: 2008-01
Estimated Completion Date: 2029-01-31
Participants
Target number of participants: 313
Treatments
Experimental: allergic asthmatic, allergic nonasthmatic, healthy
Adults who are allergic asthmatics, allergic nonasthmatics, or healthy controls will receive segmental allergen challenge to the lung
Related Therapeutic Areas
Sponsors
Collaborators: National Institutes of Health (NIH), U.S. Army Medical Research and Development Command
Leads: Benjamin Medoff

This content was sourced from clinicaltrials.gov